A technology developed in the laboratory of James Wells, PhD, chair of the Department of Pharmaceutical Chemistry, UCSF School of Pharmacy, will drive a new approach to cancer treatment that switches on or triggers, with small molecules, the enzymes called caspases that promote cell death. "Most drug discovery efforts are focused on identifying drugs that inhibit enzyme function," said Wells. "But, interestingly, many cellular enzymes remain dormant until activated.
